The EANM-SNMMI guideline on the role of [18F]FDG-PET/CT in breast cancer: Important milestones and perspectives for the future.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Evaluation of the time‑of‑flight-enhanced deep learning image reconstruction method inPhysical and engineering sciences in medicine · 2026
   Article
2. High TLG measured by PET/CT is associated with worse PFS in patients with advanced HR+ breast cancer treated by abemaciclib combined with endocrine therapy.BMC cancer · 2026
   Article
3. [European journal of nuclear medicine and molecular imaging · 2026
   Article
4. Diagnostic Challenges in a Case of Suspected Breast Cancer with Low FDG Uptake and an Incidental Thyroid Lesion: A Case Report and Literature Review.World journal of nuclear medicine · 2025
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as